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Edited by Giulio Superti-FurgaAbstract Ras association domain family 1A (RASSF1A) is a
tumour suppressor that contains an amino-terminal cysteine-rich
region, similar to the diacylglycerol (DAG)-binding domain (C1
domain) found in the protein kinase C (PKC) family of proteins,
and a carboxy-terminal Ras-association (RA) domain. In the
present study, RASSF1A was identiﬁed as a substrate for
PKC. Using classical biochemical approaches, it was established
that S197 and S203 within the RA domain of RASSF1A are
phosphorylated by PKC in vitro and in vivo. Unlike the WT pro-
tein, the S197, 203D double mutant of RASSF1A failed to mod-
ulate microtubule organization and perinuclear vimentin
collapse. By contrast, the equivalent AA mutant of RASSF1A
phenocopied the WT protein. These ﬁndings indicate that PKC
phosphorylation of RASSF1A regulates its ability to reorganize
the microtubule network.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Keywords: RASSF1A; Protein kinase C; Microtubule
organization; Vimentin1. Introduction
Ras association domain family 1A (RASSF1A) is localized
at chromosome region 3p21.3, which frequently undergoes loss
of heterozygosity in human solid tumours [1–3]. RASSF1A
contains an amino-terminal cysteine-rich region, related to
the diacylglycerol (DAG)-binding domain (C1 domain) origi-Abbreviations: RASSF1A, Ras association domain family 1A; PKC,
protein kinase C; PMA, phorbol 12-myristate 13-acetate; DAG,
diacylglycerol; DAPI, 4 0,6-diamidine-2 0-phenylindole dihydrochloride
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doi:10.1016/j.febslet.2008.05.028nally identiﬁed in the protein kinase C family of proteins,
and a carboxy-terminal Ras-association (RA) domain [1–4].
Functional analyses of RASSF1A reveal its involvement in
apoptotic signalling [5], microtubule stabilization [6–8] and mi-
totic progression [9]. Consistent with a tumour suppressor role,
RASSF1A knockout mice are highly susceptible to various tu-
mours [10].
Here, it has been established that RASSF1A is a novel sub-
strate of protein kinase C (PKC). Two PKC phosphorylation
sites within the RA domain of RASSF1A have been identiﬁed.
Phosphorylation of these sites in mammalian cells was estab-
lished using phosphorylation site-speciﬁc antibodies. The ef-
fects of mutation of these PKC sites on RASSF1A-induced
intracellular reorganization of microtubules and vimentin ﬁla-
ments are indicative of a negative regulatory role for these
phosphorylations.2. Materials and methods
2.1. Antibodies and reagents
Antibodies used were: Vimentin (Mouse monoclonal) from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA, USA); RASSF1A (mouse
monoclonal, ebiosciences, San Diego, CA, USA); a-tubulin (mouse
monoclonal), b-tubulin (mouse monoclonal) and Flag-M1 (rabbit
polyclonal) from Sigma–Aldrich (St. Louis, MO). The ProLong Gold
antifade reagent with 4 0,6-diamidine-2 0-phenylindole dihydrochloride
(DAPI) and secondary antibodies Alexa Fluor 488 Donkey Anti-
Rabbit and Alexa Fluor 555 Donkey Anti-Mouse used for immuno-
ﬂuorescence were from Invitrogen (Paisley, UK). Aﬃnity puriﬁed
horseradish peroxidase (HRP) coupled mouse and rabbit secondary
antibodies, ECL reagent and glutathione Sepharose 4B beads were
purchased from GE Healthcare (Buckinghamshire, UK). The Phos-
phatase inhibitor cocktail 1 and 2 were from Sigma–Aldrich (St. Louis,
MO). Phorbol 12-myristate 13-acetate (PMA) and Go¨ 6976 were from
Alexis (San Diego, CA); Go¨ 6983 was from Calbiochem (San Diego,
CA). Pfu Turbo DNA polymerase was purchased from Stratagene
(La Jolla, USA) and the dNTPs used in PCR were from New England
Biolabs (NEB). The transfection reagent Lipofectamine 2000 was
from Invitrogen (Paisley, UK). RapidTrans competent cells used
for transformation were purchased from Active Motif. All other com-
mon reagents were from Sigma–Aldrich (St. Louis, MO). The cell cul-
ture media were obtained from Cancer Research UK Media
Production, London.
2.2. Plasmid constructs
The construct pCDNA3-Flag-RASSF1A containing the full length
coding sequence of human RASSF1A as an EcoRI-BamHI fragment
in pCDNA3-Flag was a gift from Dr. L. Neyses (University of Man-
chester, UK). The plasmid constructs pCDNA3-Flag-RASSF1Ablished by Elsevier B.V. All rights reserved.
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F1A (S197A–S203A) and pCDNA3-Flag-RASSF1A (S197D–
S203D), were created by PCR based site-directed mutagenesis (Strata-
gene, CA, USA) using pCDNA3-Flag-RASSF1A as a template and se-
quence veriﬁed. Small-scale and large-scale plasmid DNA preparations
were accomplished using the QIAprep Spin MimiPrep (Qiagen) and
Qiagen Plasmid Maxi Kit (Qiagen), respectively, following the manu-
facturers guidelines.
2.3. In vitro kinase assay
The RASSF1A derived, 18-mer synthetic peptides (prepared by the
CR-UK Peptide Synthesis Laboratory) were assayed as PKC sub-
strates as described previously [11]. A peptide based on the PKCa
pseudosubstrate was used as a positive control in these experiments.
All assays were repeated four times.
2.4. Production of phospho-speciﬁc antibodies
The RASSF1A derived, 10-mer synthetic phospho-peptides
[GRGTpSVRRRT (RASSF1A pS197) and VRRRTpSFYLP (RASS-
F1A pS203)] were coupled to Keyhole Limpet Haemocyanin (KLH) in
PBS and immunized as described previously [11]. The immune sera
were employed routinely in the presence of 0.1 lg/ml of the corre-
sponding dephospho-peptide to enable speciﬁc detection of phospho-
RASSF1A.
2.5. Cell culture, transfections and treatments
293T (human embryonic kidney cells, expressing T-antigen) and
green monkey kidney lines Cos-7 (both obtained from CR-UK re-
search services) were routinely maintained in Dulbeccos modiﬁed Ea-
gles medium (DMEM) supplemented with 10% fetal calf serum (FCS)
at 37 C in 5% CO2. The other cells used for screening for the expres-
sion of endogenous RASSF1A were: HT29, HS578-T, HeLa, HL60,
human skin ﬁbroblasts XP25 and 46BRI-GI, HT1080, mouse ﬁbro-
blasts NIH3T3 and MEF, T47D, A549, OVCAR-3, CHO, HTB76
(all obtained from CR-UK research services) and NCL-H1437 (pur-
chased from ATCC). All the cells were cultured at 37 C in 5% CO2
in DMEM plus 10% FCS at 37 C except for OVCAR-3 which was
cultured in 2% RPMI plus 10% FCS and 1 lg/ml insulin as a supple-
ment. Transfections were performed using Lipofectamine 2000 (Invit-
rogen, Paisley, UK) according to the manufacturers instructions. For
induction and other treatments, 3 · 106 cells seeded in 10 cm dishes
were grown to 80–85% conﬂuence and stimulated with agonists for
the times indicated in the ﬁgures legends. In cases where the eﬀects
on ectopically expressed proteins were studied, the transfections and
treatments were performed in six well plates. After stimulation, the
cells were washed once with ice cold PBS and lysed in RIPA buﬀer
[150 mMNaCl, 100 mM Tris–HCl, pH 7.4, 2% NP-40, 1% deoxycholic
acid (DOC), 0.2% SDS + 2· protease inhibitor tablets, 1 mM phenyl-
methylsulfonyl ﬂuoride, 0.1 lM aprotinin, 1 lM leupeptin, 1 lM pep-
statin, 1 mM NaVO4, 1 mM Na2MoO4, 4.46 mg/ml Na4P2O7, 25 mM
b-glycerophosphate, 1· phosphatase inhibitor cocktail 1, 1· phospha-
tase inhibitor cocktail 2 (both cocktails from Sigma–Aldrich, St. Louis,
MO)] or as indicated in the ﬁgure legends. Cell lysis was performed on
ice for 30 min and the cell lysates were cleared by centrifugation at
13500 rpm for 30 min at 4 C and used immediately for further assays.
2.6. Immunoprecipitation and immunoblotting
The cell lysates from untransfected or transfected cells were prepared
in appropriate lysis buﬀer as indicated in the ﬁgure legends. The spe-
ciﬁc protein from the lysate was immunoprecipitated by incubating
the lysates with appropriate antibody for 1 h followed by incubation
with washed ProteinA+G–Sepharose beads for 30 min. The beads were
then washed three times with the lysis buﬀer and the proteins bound to
the beads were eluted in 2· Laemmli buﬀer and subjected to immuno-
blotting. HRP coupled secondary antibodies were used to detect the
binding of primary antibodies and visualization of the immunoreactive
proteins was by chemiluminescence (GE Healthcare, Buckingham-
shire, UK) and exposure to X-ray ﬁlm.
2.7. Immunoﬂuorescence
Cos-7 cells were transfected with plasmids as indicated in the ﬁgure
legends. Eighteen hours post-transfection, the cells were trypsinized
and seeded at 60% conﬂuence on acid washed glass coverslips. Cellswere allowed to grow for an additional 18 h. The cells were washed
in PBS, ﬁxed with 3.7% paraformaldehyde for 10 min and permeabili-
zed with 0.1% Triton X-100 for exactly 5 min. The coverslips were then
treated with 1% BSA in PBS for 30 min at RT followed by incubation
with an appropriate dilution of primary antibody prepared in 1% BSA.
After washing in PBS, the coverslips were incubated in the dark with
ﬂuorescent dye-conjugated secondary antibody for 45 min at RT. Fi-
nally, the coverslips were washed in 3· PBS and 1· water and mounted
onto glass slides using ProLong Gold antifade reagent with DAPI
(Invitrogen, Paisley, UK). The slides were left at RT overnight to allow
the mountant to set and the images were acquired using an upright la-
ser scanning confocal microscope (LSM 510 Carl Zeiss Jena) equipped
with a 64·/1.4 Plan-Apochromat Oil Ph3 objective. Alexa Fluor 488
was excited with the 488 nm line of an Argon laser and Alexa Fluor
555 with the 543 nm line in HeNe laser. Each image represents a single
0.38 lm Z optical section and each confocal image is representative of
at least four separate experiments.3. Results
3.1. Identiﬁcation of RASSF1A as a candidate substrate of PKC
We have shown elsewhere that RASSF1A displays retarded
migration on PAGE following calyculin treatment of cells
(manuscript in preparation). Since RASSF1A is a C1 domain
containing protein and hence may become co-localized with
C1-containing PKC isoforms, we screened the RASSF1A pro-
tein for potential PKC phosphorylation sites using an in silico
method [12]. These predictions suggested that S197 and S203
within the RA domain of RASSF1A are good candidate
PKC phosphorylation sites falling within the top 0.2 and 0.1
percentile of prediction scores, respectively [12] (data not
shown). The adjacent candidate sites T196 and T202 scored
less favourably.
In order to assess the in vitro phosphorylation of these sites
by PKC, a panel of short modiﬁed peptides comprising these
sites in RASSF1A (i.e. T196, S197, T202, S203) was con-
structed (Fig. 1A); the pseudosubstrate sequence of PKCa
was used as a positive control. It was found that both S197
and S203 were excellent in vitro substrates of PKCa (Fig.
1B). The peptides with these sites intact were phosphorylated
about six times more eﬃciently at this concentration than
the pseudosubstrate peptide employed here as positive control.
The T196 site and the T202 site were ineﬃciently phosphory-
lated by PKCa (Fig. 1B). These results demonstrated that
S197 and S203 but not T196 and T202 represent good in vitro
PKCa phosphorylation sites.
3.2.PMA induces phosphorylation of exogenous and endogenous
RASSF1A at S197 and S203
In order to investigate whether RASSF1A could become
phosphorylated on S197 and S203 in mammalian cells, phos-
pho-speciﬁc antibodies were raised and tested on WT and mu-
tant RASSF1A in 293T cells. An enhanced signal representing
phospho-Flag-RASSF1A was detected following induction of
cells with the PKC activator PMA or PMA + calyculin A
and immunoblotting with the two immune sera designed to de-
tect phosphorylation on S197 and S203 (Fig. 1C). The speciﬁc-
ity of these antisera towards these two RASSF1A sites was
evidenced by the lack of any change in immunoreactivity asso-
ciated with PMA ± calyculin treatment of the AA mutant
expressing cells (Fig. 1C). It was notable that there was basal
phosphorylation of Flag-RASSF1A at S203. This varied from
experiment to experiment; in some experiments, this site was
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Fig. 1. RASSF1A is a novel substrate of PKC. (A) Sequence(s) of synthetic short peptides comprising the potential PKC phosphorylation sites
within RASSF1A. The predicted sites in these peptides were either left or were mutated to alanine residues as indicated. These peptides were used for
in vitro kinase assays. (B) In vitro kinase assays for PKCa with the peptides shown in panel A. The reactions were performed as described in Section
2. The reactions without peptide or without the enzyme were used as negative controls and a peptide based on the PKCa pseudosubstrate was used as
a positive control in these experiments. The experiments were repeated four times. (C) PMA induced phosphorylation of RASSF1A as determined by
the immune sera raised against phospho-RASSF1A S197 and phospho-RASSF1A S203, respectively. 293T cells grown to 90% conﬂuence were left
untransfected (denoted as U) or were transfected with wild type Flag-RASSF1A (WT) or with the dual alanine mutant version of RASSF1A
(S197A–S203A; AA). Twenty-four hours after transfection, the cells were treated with or without 0.8 lM PMA or 0.8 lM PMA + 100 nM calyculin
A (as indicated) for 30 min and the lysates prepared were subjected to immunoblotting with antisera as indicated. The position of Flag-tagged
phospho-RASSF1A in the gel is shown with an arrow. (D) Phorbol 12-myristate 13-acetate (PMA) induces phosphorylation of endogenous
RASSF1A at S197 and S203. NIH3T3 cells grown to 90% conﬂuence were treated with or without 0.8 lM PMA for 30 min and the lysates prepared
in 1x RIPA buﬀer with protease and phosphatase inhibitors (Section 2). Lysates were subjected to immunoprecipitation with RASSF1A antibody
and immunoblotted to detect phosphorylation. A b-tubulin blot of the input lysate is shown.
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phosphorylation of this site was detected (as evident in the ﬁg-
ures presented below). The exact cause of the variable basal
phosphorylation of this site remains to be established (see Sec-
tion 4).
To determine whether endogenous RASSF1A is phosphory-
lated on these sites, a panel of human and mouse, normal and
transformed cell lines were screened for expression of RASS-
F1A protein; the highest levels of RASSF1A were detected
in mouse embryonic ﬁbroblast lines and NIH3T3 (data not
shown). It was established that in NIH3T3 cells the endoge-
nous RASSF1A is phosphorylated on S197 and S203 in a
PMA dependent manner (Fig. 1D).
3.3. Kinetics of PMA induced phosphorylation of RASSF1A at
S197 and S203
A time course of PMA induced phosphorylation of Flag-
RASSF1A in 293T cells suggested that S197 is phosphorylated
as early as 30 s after PMA stimulation, this reaches a peak at
10 min and is sustained for at least 2 h (Fig. 2A, Upper pa-nel). Because of a higher level of basal phosphorylation of
RASSF1A on S203 in all these experiments, a consistent diﬀer-
ence in the signal of RASSF1A pS203 from uninduced or in-
duced cells was not apparent (Fig. 2A, Middle panel).
3.4. PMA induced phosphorylation of RASSF1A on S197 and
S203 is inhibited by various inhibitors of PKC
Results presented above demonstrate that RASSF1A pep-
tides comprising S197 and S203 are excellent substrates of
PKCa in vitro and that RASSF1A is phosphorylated at
S197 and S203 in a PMA dependent manner in cells. To assess
the requirement for PKC activity a panel of known isotype-
selective PKC inhibitors was employed. Go¨ 6976 inhibits
conventional PKC (cPKC) but shows much reduced activity
towards novel (nPKC) and atypical PKC (aPKC) isotypes d,
e or f [13]. Go¨ 6983 has been shown to selectively inhibit
several PKC isoenzymes (aPKC, nPKC and cPKC) and does
not inhibit PKCl eﬀectively permitting diﬀerentiation of
PKCl from other isoforms [14–16]. Bisindolylmaleimide I
(BIM) is known to selectivity inhibit conventional and novel
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Fig. 2. Kinetics of PMA induced phosphorylation of RASSF1A. (A)
A time course of PMA induced phosphorylation of Flag-tagged
RASSF1A at S197 and S203 in 293T cells. 293T cells grown to 90%
conﬂuence were transfected with Flag-tagged RASSF1A. At 24 h after
transfection, the cells were treated with 0.8 lM PMA for the times
indicated. The lysates prepared in 1· RIPA buﬀer with protease and
phosphatase inhibitors (Section 2) were subjected to immunoprecip-
itation with RASSF1A antibody and immunoblotted with pS197
speciﬁc antiserum (Upper panel) or pS203 antiserum (Middle panel). A
small fraction of cell lysates from these experiments was subjected to
immunoblotting with RASSF1A antibody (Lower panel). (B) Inhibi-
tion of PMA induced phosphorylation of RASSF1A S197 and
RASSF1A S203 by various inhibitors of PKC (see text). 293T cells
transfected with Flag-tagged RASSF1A were treated with DMSO, or
with the PKC inhibitor Go¨ 6976 (0.1 lM), bisindolylmaleimide I
(0.2 lM), or Go¨ 6983 (0.6 lM) for 30 min prior to induction with
0.8 lM PMA for 30 min as indicated. Lysates prepared in 1· RIPA
buﬀer with protease and phosphatase inhibitors (Section 2) were
immunoblotted with pS197 speciﬁc immune serum (panel 1) or with
pS203 speciﬁc antiserum (panel 4). The remaining lysates were
immunoprecipitated with RASSF1A antibody and immunoblotted
with anti-p197 (panel 3) or with anti-p203 (panel 6) as indicated. The
lysate blots showing Flag-tagged RASSF1A protein are shown in
panels 2 and 4.
Flag-RASSF1A pS197
50
37
50
37
50
37
IB:PPA 545
Flag-RASSF1A pS203
Flag-RASSF1A
IB:PPA 548
U
U/T PMA
IB:RASSF1A
Ve
cto
r
W
T
AS SA AA U Ve
cto
r
W
T
AS SA AA
Fig. 3. Order of PMA induced phosphorylation of RASSF1A at S197
and S203. 293T cells grown to 90% conﬂuence were either left
untransfected (U) or were transfected with empty vector, wild type
Flag-tagged RASSF1A (WT) or with the AS or SA mutants of Flag-
RASSF1A (representing Flag-RASSF1A S197A-S203S and Flag-
RASSF1A S197S–S203A, respectively) as indicated. Twenty-four
hours after transfection these cells were either left untreated (U/T) or
were treated with 0.8 lM PMA for 30 min as indicated and lysed in 1·
RIPA buﬀer with protease and phosphatase inhibitors (Section 2). The
cell lysates were subjected to immunoprecipitation with RASSF1A
antibody followed by immunoblotting with the immune sera as
indicated.
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Flag-tagged RASSF1A at S197 and S203 was completely
(Go¨6983, BIM1) or partially (Go¨6976) inhibited by these
PKC inhibitors (Fig. 2B) suggesting that PMA induced phos-
phorylation of RASSF1A at S197 and S203 is mediated by one
or more isoform of PKC including c/nPKC isoforms. Notehowever that the basal phosphorylation of both sites appears
to be insensitive to the action of these inhibitors and hence that
PKC isoforms may elicit the induced eﬀect but not the basal
phosphorylation under these conditions.
3.5. Interdependence of the phosphorylation of RASSF1A at
S197 and S203
In order to investigate the order of PMA induced phosphor-
ylation of these sites on RASSF1A, mutant ‘‘AS’’ or ‘‘SA’’ ver-
sions of RASSF1A representing Flag-RASSF1A S197A–
S203S and Flag-RASSF1A S197S–S203A, respectively, were
constructed. The phosphorylation of the AS mutant of Flag-
RASSF1A was detected by anti-pS203 immune serum but as
expected could not be detected by anti-pS197 (Fig. 3), further
conﬁrming that anti-pS197 speciﬁcally detects RASSF1A
phosphorylation on S197 and it does not cross react with
RASSF1A pS203. Similarly, the PMA induced phosphoryla-
tion of the SA mutant was detected by anti-pS197 but not
by anti-pS203. Together, these results demonstrated that these
immune sera speciﬁcally detect the phosphorylation of RASS-
F1A at S197 and S203 and that both of these sites of RASS-
F1A are phosphorylated in 293T cells in response to PMA.
Interestingly, the SA mutant of Flag-RASSF1A was poorly
phosphorylated at S197 in response to PMA compared to wild
type Flag-RASSF1A (Fig. 3, panel 1), indicating that eﬃcient
PMA induced phosphorylation of RASSF1A on S197 may
only take place if the adjacent phosphorylation site S203 is in-
tact/phosphorylated. This would provide a rationale for the
frequently elevated basal S203 phosphorylation (as a priming
site) but the consistently inducible S197 phosphorylation.
3.6. An S197D–S203D mutant of RASSF1A fails to modulate
microtubule organization
Previous studies show that RASSF1A associates with micro-
tubules in interphase cells and plays a critical role in microtu-
bule dynamics [6–8,21]. Here, it was conﬁrmed that ectopically
expressed Flag-RASSF1A indeed co-localizes with microtu-
bules (Fig. 4). Further, it was observed that ectopic expression
of Flag-RASSF1A in Cos-7 cells caused rearrangement of the
Fig. 4. Eﬀect of S197A–S203A (Flag-RASSF1A-AA) and S197D–S203D (Flag-RASSF1A-DD) mutants on the microtubule network. (A) Cos-7
cells transfected with the empty vector (a, b; i, j), vector expressing Flag-RASSF1A (c, d; k, l), Flag-RASSF1A (AA) mutant (e, f; m, n), or Flag-
RASSF1A (DD) mutant (g, h; o, p) were immunostained for the protein(s) as indicated and analysed by confocal microscopy (LSM510, Carl Zeiss
Jena). Wild type and mutated Flag-RASSF1A was visualized by a Flag-M1 antibody (Rabbit polyclonal, Sigma–Aldrich), microtubules by an a-
tubulin antibody (Mouse monoclonal, Sigma–Aldrich) and vimentin by a mouse monoclonal (Santa Cruz). Nuclei in l were counterstained by
DAPI. Two-colour/multicolour superimposed images (Merge) are shown as indicated. The scale bar is equivalent to 20 lm.
2274 S.K. Verma et al. / FEBS Letters 582 (2008) 2270–2276microtubules into circular rings, whereas the untransfected or
vector transfected cells show microtubules radiating from a
microtubule-organizing center (MTOC) [22] (Fig. 4). To assess
the eﬀect of S197 and S203 phosphorylation on RASSF1A in a
speciﬁc manner, a mutated version of Flag-RASSF1A was cre-
ated in which the serines at position 197 and 203 were replaced
with phosphomimetic aspartic acid residues (denoted
RASSF1A-DD) or with alanine residues as a control (RASS-
F1A-AA). It was found that both, RASSF1A-AA and RASS-
F1A-DD mutants were associated with microtubules (Fig. 4).
However, in contrast to the Flag-tagged wild type RASSF1A
and Flag-RASSF1A-AA, the Flag-RASSF1A-DD mutant
does not lead to the circularization of the microtubule network
(Fig. 4) clearly indicating a loss of function. RASSF1A in-
duced alterations in microtubule dynamics inﬂuence other
microtubule-dependent processes such as the distribution of
vimentin and Golgi integrity. As shown in Fig. 4, ectopic
expression of the AA mutant of Flag-RASSF1A leads to a
strong perinuclear collapse of vimentin ﬁlaments as was ob-
served with wild type Flag-RASSF1A (Fig. 4). However, the
DD mutant of Flag-RASSF1 failed to cause the perinuclear
collapse of the vimentin ﬁlaments (Fig. 4). This indicates that
phosphorylation of RASSF1A at S197 and S203 prevents
RASSF1A regulation of the intracellular distribution and
dynamics of microtubules and consequently the vimentin net-
work.4. Discussion
As a tumour suppressor, the control of RASSF1A is of sig-
niﬁcant interest in deriving an understanding of both physio-logical action and pathological inaction. Functionally
RASSF1A is know to inﬂuence apoptosis [5], mitosis [9] and
has speciﬁc eﬀects on microtubule organization and dynamics
[6–8]. The phosphorylation site mapping on RASSF1A re-
ported here deﬁnes two sites juxtaposed to the RA domain that
when stoichiometrically occupied using phospho-mimetic resi-
dues, causes inactivation of the microtubule reorganising prop-
erties of RASSF1A. The implication is that this loss of
function may contribute to the repertoire of mechanisms en-
gaged to inactivate RASSF1A in tumourigenesis.
RASSF1A is a C1 domain containing protein that like cer-
tain other C1 domain-containing proteins was postulated to
be co-regulated by DAG or phorbol esters as exempliﬁed
by PMA induced phosphorylation of RasGRP3 [23] and
PKD [24]. To test this, the in silico method of Fujii et al.
was employed initially since it has an advantage over other
known algorithms in being based on sets of experimentally
(in vitro and in vivo) proven S, T and Y phosphorylation
sites from the literature and from curated database(s) e.g.
Swiss-Prot [25] and PhosphoBase [26]. This method facilitates
prediction of PKC phosphorylation sites with greater speciﬁc-
ity and sensitivity (80–90%), particularly if they fall within
the top 0.2 percentile [12]. Using a very stringent cut-oﬀ score
of 0.2 percentile, predictions suggested that S197 and S203
within the RA domain of RASSF1A might be potential
PKC phosphorylation sites. In vitro kinase assays demon-
strated that these sites were excellent substrates of PKCa,
in fact better than the routinely employed pseudosubstrate
peptide. Using classical biochemical approaches, it was estab-
lished that S197 and S203 within the RA domain of RASS-
F1A can be phosphorylated in response to PKC activation
in cells.
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protein comes from the study of Kim et al. where it was pro-
posed that serine 131 of RASSF1A might be a substrate for
the ATM kinase because the sequence WETPDLSQAEIEQK
(amino acids 135–138 of RASSF1A) matches the ATM family
phosphorylation site consensus sequence; a peptide with this
sequence is an excellent ATM substrate in vitro [27]. A recent
study has indeed shown that the S131F mutant of RASSF1A
remains poorly phosphorylated in vivo compared to that of
the wild type protein [9]. During the preparation of this man-
uscript, it was further reported that the mitotic kinase Aurora-
A directly interacts with and phosphorylates RASSF1A during
mitosis [28]. Interestingly, the authors showed by in vitro
kinase assays that the double-point mutation on both
Thr202 and Ser203 (T202A/S203A) completely abolished Aur-
ora-A-mediated phosphorylation of RASSF1A suggesting that
either T202 or S203 is essential for Aurora-A-mediated phos-
phorylation of RASSF1A. Using phosphomimetic mutations,
the authors also linked the Aurora-A phosphorylation of
RASSF1A with the regulation of RASSF1A interaction with
microtubules [28].
In contrast to the above studies on Aurora-A, it is notable
that the eﬀects of phosphomimetic residues at S197 and S203
as reported here, do not inﬂuence the co-localization of RASS-
F1A with the microtubule network. Rather, it is demonstrated
that they exert their eﬀects on RASSF1A by blocking its ability
to reorganize the microtubule network. The basis of this dis-
tinction may lie in the additional T202 site mutated in the Aur-
ora-A study [28]. Notwithstanding this consideration, the
phosphorylations identiﬁed here display an inter-dependence
indicating that there may be a hierarchical input for Aurora-
A and PKC in controlling RASSF1A. Thus when S203 is mu-
tated to an alanine (i.e. cannot be phosphorylated) S197 is
poorly phosphorylated following PKC activation in cells. In
view of the eﬃcient phosphorylation of S197 in vitro it would
appear that S203 phosphorylation inﬂuences the availability of
the S197 site.
In conclusion, the study here provides novel insights into the
regulation of RASSF1A. The RA domain phosphorylation
sites evidently play a key role in determining RASSF1A con-
trol of microtubule organization.
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